佳醫集團

用心 Dedication | 自主 Discipline | 創新 Innovation | 前瞻 Proactive

Excelsior Medical Co., Ltd.

Investor Conference

2026/9/15

Disclaimer

This presentation is prepared according to the audited or reviewed financial statements by CPA and the financial figures hereby are based on IFRS, please refer to the published financial statements for full content.

The presentation may contain forward-looking information and may differ materially from the actual results. Excelsior does not warranty as to the accuracy or completeness of such information and nor assume any undertaking further information becomes available or in light of changing circumstances. You shall not place undue reliance on any forward-looking information.

The presentation and its contents may not be reproduced to a third party without the prior written consent by Excelsior.

The Business Types

Revenue Overview

Excelsior yearly consolidated sales is more than NT $ 8.7 billion in 2025, the primary revenue comes from Excelsior (Hemodialysis), Dynamic (Aesthetic Medical), Arich (Pharmaceutical Logistics), ABL(Long-term Care) and others. According to the company's function, the business type can be characterized as a trading business, medical service provider and pharmaceutical logistics.



Operating Overview

Unit: NTD in thousands



佳醫健康事業
Excelsior Medical

Investment Overview

Unit: NTD in thousands



Note: Excelsior Medical Co., Ltd. consolidated ABL on May 29, 2026, by obtaining a majority of the seats on its Board of Directors.

佳醫集團
Excelsior Healthcare Group

Profit after Tax Overview

Unit: NTD in thousands/
EPS: NTD in Dollars



佳醫健康事業
Excelsior Medical

Balance Sheet

Unit: In thousands NTD	2026.06.30	2025.12.31	2024.12.31
Assets			
Current Assets:			
Cash and cash equivalents	3,335,734	2,847,128	4,189,204
Receivables	2,226,297	1,957,907	1,945,932
Other receivables	3,197,288	3,250,068	3,661,059
Inventories	1,428,797	1,391,669	1,392,801
Other current assets	1,483,910	919,520	1,031,944
Total Current Assets	11,672,026	10,366,292	12,220,940
Non-Current Assets			
Non-current financial assets at fair value through other comprehensive income	781,993	881,474	655,910
Investments accounted for using equity method	3,116,976	4,216,105	4,043,825
Property, plant and equipment	920,960	756,005	795,597
Investment property, net	1,592,090	1,598,242	1,610,545
Other non-current assets	3,071,836	1,159,079	1,041,184
Total Non-Current Assets	9,483,855	8,610,905	8,147,061
Total Assets	21,155,881	18,977,197	20,368,001

Balance Sheet

Unit: In thousands NTD	2026.06.30	2025.12.31	2024.12.31
Liabilities			
Current Liabilities			
Short- term borrowings	641,550	1,343,221	917,531
Payables	1,022,888	1,146,354	978,970
Other payables	3,106,206	2,596,329	5,307,269
Other current liabilities	1,219,622	1,106,099	1,084,891
Total Current Liabilities	5,990,266	6,192,003	8,288,661
Non-Current Liabilities			
Long- term borrowings	350,000	350,000	-
Other non- current assets	1,611,395	710,587	721,987
Total Non-Current Liabilities	1,961,395	1,060,587	721,987
Total Liabilities	7,951,661	7,252,590	9,010,648
Equity Attributable to Owners of Parent			
Share capital	1,883,674	1,715,674	1,633,975
Capital surplus	4,248,985	3,390,833	3,382,788
Retained earnings	3,464,065	3,740,835	3,619,990
Other equity	216,767	344,945	333,488
Total Equity Attributable to Owners of Parent	9,813,491	9,192,287	8,970,241
Non- controlling interests	3,390,729	2,532,320	2,387,112
Total Equity	13,204,220	11,724,607	11,357,353
Total Liabilities and Equity	21,155,881	18,977,197	20,368,001

Statement of Comprehensive Income

Unit: In thousands NTD	2026 Q2	2025	2024
Operating revenue	4,729,202	8,789,236	8,538,546
Operating costs	3,715,216	6,916,602	6,753,082
Gross Profit	1,013,986	1,872,634	1,785,464
Gross Margin	21.44%	21.31%	20.91%
Operating expenses	640,086	1,145,095	1,032,148
Operating Income	373,900	727,539	753,316
Non- operating income and expenses	338,007	454,368	421,046
Profit before tax	711,907	1,181,907	1,174,362
Tax expense	129,841	216,300	203,307
Net profit after tax	582,066	965,607	971,055
Net Profit Attributable to Owners of Parent	513,677	805,860	771,259
EPS (Dollars)	2.77	4.70	4.50

Statements of Cash Flows

Unit: In thousands NTD	2026 Q2	2025	2024
Profit before tax	711,907	1,181,907	1,174,362
Adjustments	(138,175)	(138,064)	(99,191)
Cash Flows from Operating Activities			
Receivables	13,386	34,337	16,289
Other receivables	53,325	407,845	199,157
Inventories	(45,509)	(88,467)	(264,071)
Payables	(135,957)	167,384	4,244
Other payables	289,441	(2,711,336)	1,661,961
Income taxes paid	(113,384)	(204,577)	(228,431)
Others	(89,424)	(12,659)	7,125
Net Cash Flows from (used in) Operating Activities	545,610	(1,363,630)	2,471,445

佳醫集團 Excelsior Healthcare Group

Statements of Cash Flows

Unit: In thousands NTD	2026 Q2	2025	2024
Cash Flows from Investing Activities			
Acquisition of financial assets at fair value through profit or loss	-	(3,421)	1,738
Proceeds from disposal of financial assets at fair value through profit or loss	19	1,673	-
Acquisition of financial assets at fair value through other comprehensive income	(79,463)	(855)	(2,387)
Proceeds from disposal of financial assets at fair value through other comprehensive income	84,705	48,930	-
Acquisition of financial assets at amortized cost	(169,027)	(513,467)	(592,789)
Proceeds from disposal of financial assets at amortized cost	153,027	655,353	612,075
Acquisition of investments accounted for using equity method	-	(8,000)	-
Proceeds from disposal of investments accounted for using equity method	-	-	11,701
Net cash flow from acquisition of subsidiaries	572,788	-	-
Acquisition of property, plant and equipment	(64,857)	(77,787)	(114,866)
Proceeds from disposal of property, plant and equipment	54	-	1,027
Refundable deposits	(5,912)	(109,747)	11,807
Acquisition of investment properties	-	-	(249,160)
Other financial assets	7,628	27,029	(76,734)
Dividends received	192,312	209,113	325,709
Others	(354)	(3,929)	6,312
Net Cash Flows from (used in) Investing Activities	690,920	224,892	(65,567)

佳醫健康事業 Excelsior Medical

Statements of Cash Flows

Unit: In thousands NTD	2026 Q2	2025	2024
Cash Flows from Financing Activities			
Short- term borrowings	(701,671)	425,690	(217,356)
Proceeds from long term borrowings	-	350,000	-
Cash dividends paid	(808,711)	(620,910)	(591,344)
Proceeds from disposal of ownership interests	-	-	159,086
Capital increased by cash	1,008,000	-	-
Others	(219,443)	(303,764)	(306,342)
Net Cash Flows used in Financing Activities	(721,825)	(148,984)	(955,956)
Effect of exchange rate changes on cash and cash equivalents	(26,099)	(54,354)	124,496
Net increase (decrease) in cash and cash	488,606	(1,342,076)	1,574,418
Cash and cash equivalents at beginning of period	2,847,128	4,189,204	2,614,786
Cash and cash equivalents at end of period	3,335,734	2,847,128	4,189,204

Sustainability Report

格瑞國際驗證有限公司
GREAT International Certification Co., Ltd.

佳醫健康事業股份有限公司
2025 年永續報告書之獨立保證意見聲明書

聲明書編號:2605013

佳醫健康事業股份有限公司(以下簡稱佳醫健康)與格瑞國際驗證有限公司(以下簡稱格瑞驗證)為相互獨立的公司及組織，格瑞驗證除了針對該公司 2025 年永續報告書進行評估和查證外，與佳醫健康並無任何財務上的關係。

本獨立保證意見聲明書(以下簡稱聲明書)的目的，僅作為對下列有關佳醫健康之永續報告書所界定範圍內的相關事項進行保證之結論，而不作為其他之用途。除對查證事實提出聲明書外，對於其他目的之使用，或閱讀此聲明書的任何人，格瑞驗證並不負有或承擔任何相關法律或其他之責任。

保證範圍

意見聲明

查證方法

結論

包容性

第一頁(共二頁)

格瑞國際驗證有限公司
GREAT International Certification Co., Ltd.

重大性

回應性

衝擊性

GRI 永續性報導準則

SASB 準則

保證等級

責任

能力與獨立性

第二頁(共二頁)

AA1000
Licensed Report
000-250/V3-IX6VP

格瑞國際驗證有限公司
GREAT International Certification Co., Ltd.

聲明書編號：Great-GHGER-26-0405

溫室氣體排放與移除查證聲明書

佳醫健康事業股份有限公司

溫室氣體排放和移除的盤查在以下地點進行：

新北市中和區中正路 880 號 17 樓、16-5、-6、-7 樓、11 樓、10-7 樓 (總部)

台中市南區復興路一段 270 號 3 樓、6 樓 B 室 (台中辦公室)

台南市仁德區文華路 3 段 589 號 (台南辦公室)

高雄市三民區建國一路 458 號 11 樓及 13 樓 (高雄辦公室)

高雄市苓雅區福德一路 123 號 (高雄倉庫)

已根據 ISO 14064-3:2019 於 2026 年 04 月 15、22 日進行查證，符合以下標準要求：

ISO 14064-1:2018

溫室氣體排放資訊：

直接排放(類別 1)：　18.5409 噸二氧化碳當量；

間接排放(類別 2)：　193.9659 噸二氧化碳當量；

其他間接排放類別(類別 3~類別 6)將於下一頁圖表列。

- 查證目標：格瑞以獨立第三方立場，公正客觀地收集、查證支持溫室氣體主張所揭露之資訊，確保報告資訊符合準確性、完整性、一致性及透明度之準則，且內容無錯誤或遺漏之虞。
- 報導期間：2025 年 01 月 01 日至 2025 年 12 月 31 日。
- 類別 1 和類別 2 以合理保證等級進行查證，類別 3 和類別 4 以有限保證等級進行查證。
- 不確定性評估：95%信心水準，類別一：-2.79%~+5.39%，類別二：-7.07%~+7.07%。
- 實質性：5%。

總經理　陳文俊

首次發行日期：2023 年 07 月 15 日；最新發布日期：2026 年 04 月 30 日

Page 1 of 3

This verification statement is invalid without the full scopes, categories, criteria, level of assurance and findings available on the Statement.
Verification Body: Great International Certification Co., Ltd. Address: 4F., No. 28, Dahua 1st St., Dayuan Dist., Taoyuan City 337002, Taiwan (R.O.C.)

格瑞國際驗證有限公司
GREAT International Certification Co., Ltd.

聲明書編號：Great-GHGER-26-0405

- 報導溫室氣體的類型，包括 CO_2、CH_4、N_2O 和 HFCs。
- 排放係數：2025 年經濟部能源署公告之 2024 年度電力排放係數為 0.474 $kgCO_2e/kWh$；其他排放係數參見環境部事業溫室氣體排放量資訊平台公布的年度係數，各種溫室氣體的 GWP 值是根據 IPCC 第六次評估報告所得。
- 本聲明是基於對已查證客戶提供的相關資訊進行查證後得出的結論，因此，格瑞驗證認為盤查資訊是完整有效的。
- 對本聲明書內容或相關關注的問題和疑問，均需由此受查證客戶回答(客戶類別代碼：A-27)。
- 該客戶報導的溫室氣體排放和移除量期間為：2025 年 1 月 1 日至 2025 年 12 月 31 日。

單位: 噸 CO_2e

按類別和子類別劃分的報告邊界		備註	溫室氣體排放量
類別 1：直接溫室氣體排放與移除			18.5409
1.1	固定燃燒的直接排放		不適用*
1.2	移動燃燒的直接排放	公務車汽油	10.0113
1.3	產業過程之直接過程排放和移除		不適用*
1.4	人為系統所釋放的溫室氣體的释放直接暫時逸散排放	冷氣機、冰水機、冷凍冷藏設備、公務車、滅火器、化糞池	8.5296
1.5	土地利用、土地利用變化和林業的直接排放和移除		不適用*
類別 2：來自輸入能源的間接溫室氣體排放			193.9659
2.1	輸入電力的間接排放	電力	193.9659
2.2	輸入能源的間接排放		不適用*
類別 3：交通運輸產生的間接溫室氣體排放			437.9400
3.1	上游運輸和配送貨物的排放		非顯著*
3.2	下游貨物運輸和配送的排放		非顯著*
3.3	員工通勤排放		非顯著*
3.4	客戶和訪客交通工具的排放		非顯著*
3.5	商務旅行排放	差旅(飛機、高鐵、自行開車)	437.9400
類別 4：組織使用的產品的間接溫室氣體排放			75.2381
4.1	商品採購的排放量	電力、紙張購買、汽油間接碳足跡	50.3734
4.2	資本貨物的排放		非顯著*
4.3	固體和液體廢棄物處置產生的排放	生活垃圾最終處置	24.8647
4.4	資產使用產生的排放		非顯著*
4.5	上述子類別中未描述的使用服務產生的排放		非顯著*
類別 5：與使用組織產品相關的間接溫室氣體排放			非顯著*
5.1	來自產品使用階段的排放與移除		非顯著*
5.2	來自下游租賃資產的排放		非顯著*
5.3	來自產品生命終點階段的排放		非顯著*
5.4	來自投資的排放		非顯著*
類別 6：其他來源的間接溫室氣體排放			不適用*
直接移除			不適用*
年終總存儲量			不適用*
碳財務工具			不適用*

佳醫集團 Excelsior Healthcare Group

Concrete ESG Implementation Results

1.In 2023, our company successfully completed the ISO 14064-1 GHG inventory and assurance status ahead of schedule. We will continue to promote the completion of GHG inventories across all subsidiaries within the group.

2.In 2023, our company implemented a smart energy-saving system for cooling water pumps in office buildings. In 2024, we replaced office lighting with energy-efficient fixtures. In 2025, we completed the replacement of elevators with energy-saving models, continuing to implement energy conservation and carbon reduction measures to protect the planet through concrete actions.

3.To reduce paper consumption, customer orders are approved online, supplier purchase orders are issued via email, Delivery Order have been changed from five-part to three-part forms, payroll inquiries are now conducted through the HR app. Daily cash and bank reports are now filed electronically, and our ERP processes are continually optimized to minimize environmental burden.

佳醫健康事業 Excelsior Medical

佳醫集團
Excelsior Healthcare Group

Concrete ESG Implementation Results

1. In 2023, we visited Taipei Zhaoru Senior Care Center to accompany the elderly in a dumpling-making event. In 2024, we organized a Dragon Boat Festival rice dumpling-making activity at Zhongli Smart Aging Academy for seniors with dementia and a recreational event at Bali Nursing Home. In 2025, we collaborated with the Excelsior Foundation to host a joint public welfare event for World Alzheimer's Day.
2. Every year, through the Excelsior Foundation, we organize winter relief programs to support underprivileged individuals and elderly people living alone. We also provide scholarships for students from economically disadvantaged families and dialysis patients, encouraging them to complete their education.
3. We continue to host annual blood donation drives within our office parks and donate medical resources to healthcare institutions to support patient care.
4. Our group holds an annual Family Day to emphasize the importance of family support for employees, foster team cohesion, and strengthen corporate culture.

佳醫健康事業
Excelsior Medical

Concrete ESG Implementation Results

Governance

1.In 2022, we published our first Sustainability Report. In 2023, we emphasized SASB (Sustainability Accounting Standards Board) and TCFD (Task Force on Climate-Related Financial Disclosures) standards.

2.In 2023, we established the Sustainability Development Committee under the Board of Directors to drive sustainability initiatives, strengthen supplier management, enhance risk management, engage with stakeholders, ensure information security, and uphold ethical business practices, including a whistleblower system for unethical conduct. In 2024, we obtained ISO 27001 certification for our information security management system and successfully renewed through reassessment in 2025.

3.In 2025, we ranked within the top 36%–50% in the 12th Corporate Governance Evaluation for listed companies. We will continue our efforts to enhance overall governance standards.

Growing up with Long-term partners

Excelsior has been operating for 30 years, accumulated core competitiveness with new ideas created, new models to integrate various professional medical fields. Excelsior will keep taking root in the Asia market, the business scope includes Taiwan, Hong Kong, China, Philippines and Malaysia. Through continuously cooperate and integrate with long-term partners, Excelsior expects to become the Asia's most valuable Integrated medical healthcare group.

佳醫集團

亞洲最有價值 健康醫療產業投資經營團隊

www.excelsior.com.tw